An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer

Current Medical Research and Opinion

Volumn 27, Issue 11, 2011, Pages 2193-2201

  Nuijten, Mark J C ^a   Aultman, Rick ^b   Carpeo, Javier De Castro ^c   Vergnengre, Alain ^d   Chouaid, Christos ^e   Walzer, Stefan ^b   Siebert, Uwe ^f,g  

^a Ars Accessus Medica ^*  (Netherlands)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Hpital du Cluzeau   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^g Oncotyrol Center for Personalized Cancer Medicine   (Austria)

Author keywords

Bevacizumab; Effectiveness; Indirect comparison; Non small cell lung cancer (NSCLC); Pemetrexed

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; PACLITAXEL; PEMETREXED;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; RECURRENT CANCER; SURVIVAL TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; GLUTAMATES; GUANINE; HUMANS; MARKOV CHAINS; PACLITAXEL; TREATMENT OUTCOME;

EID: 80054705103     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.626019     Document Type: Article

References (37)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8 (Pubitemid 40458328)
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92 (Pubitemid 46359643)
3. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol 2003; 14(Suppl 5):v61-v118 (Pubitemid 46417464)
4. FDA. FDA approves bevacizumab (Avastin) as a first-line treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer in combination with platinum-based chemotherapy. 2006. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm094950.htm [Last accessed 1 March 2011]
5. EMA. Assessment report for Avastin. 2008. Available at: http://www.ema. europa.eu/humandocs/PDFs/EPAR/avastin/Avastin-H-582-II-25-AR.pdf [Last accessed 28 February 2011]
6. EMEA. PRESS RELEASE (pemetrexed) Meeting highlights from the Committee for Medicinal Products for Human Use, 26-29 May 2009. Available at: http://www.emea.europa.eu/pdfs/human/press/pr/33058009en.pdf [Last accessed 18 February 2011]
7. FDA. Highlights of Prescribing Information (ALIMTA, pemetrexed disodium). 2009. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 021462s021lbl.pdf [Last accessed 9 February 2011]
8. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-14
9. Ferrara N, Hillian K, Gerber H, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400 (Pubitemid 38618122)
10. Reck M, von PJ, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50 (Pubitemid 44917502)
12. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-9
13. Crino L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010;e11:733-40
14. Griesinger F, Laskin JJ, Pavlakis N. Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL). J Clin Oncol 2008;26(15S):8049
15. EMA. Committee for medicinal products for human use post-authorisation summary of positive opinion for Alimta. 2008. Available at: http://www.ema. europa.eu/pdfs/human/opinion/Alimta-9292908en.pdf [Last accessed 15 February 2011]
16. CADTH. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. 2009. Available at: http://www.cadth.ca/media/pdf/H0462fitc-tr-e. pdf [Last accessed 8 February 2011]
17. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. 2008. Available at: http://www.nice.org. uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Last accessed 15 February 2011]
18. Sandler A, Yi J, Dahlberg SE, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010;9:1416-23
19. Scagliotti GV, Parikh P, von PJ, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51
20. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8 (Pubitemid 34438899)
21. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91 (Pubitemid 27341818)
22. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472
23. Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993;13:322-38 (Pubitemid 24013155)
24. Nuijten MJC, McCormick J, Waibel F, et al. Economic evaluation of letrozole in the treatment of advanced breast cancer in post-menopausal women in Canada. Value Health 2000;3:31-9 (Pubitemid 30232946)
25. Nuijten MJC, Meester L, Waibel F, et al. Cost-effectiveness of letrozole in the treatment of advanced breast cancer in post-menopausal women in the UK. PharmacoEconomics 1999;16(4):379-97
26. Alexander RJ, Herbst RS. Expert insight into: new guidelines in the treatment of non-small-cell lung cancer (NSCLC). The Advanced Certificate Program: Lung Cancer Management. 2008. Available at: http://www. projectsinknowledge. com/cp/Activity/index.cfm?jn1/41868&sj1/41871.01 [Last accessed 7 May 2009]
27. Stinchcombe TE, Socinski MA. Current treatments for advanced stage nonsmall cell lung cancer. Proc Am Thorac Soc 2009;6:233-41
28. Skaff ZG, Hageboutros A, Krieger K, et al. A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(Suppl):abstract e19091
29. Collins R, Fenwick E, Trowman R, et al. A systematic review and economic model of the clinical effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 2007;11(2):1-179
30. Mickisch GH, Schwander B, Walzer S. Metastatic renal cell carcinoma: a comparative effectiveness assessment of first-line bevacizumab \+ interferon alpha-2A vs sunitinib. Eur J Cancer Suppl 2009;7:437
31. Ward S, Simpson E, Davis S, et al. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007;11(40):1-144
32. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002;21:1575-600 (Pubitemid 34746064)
33. Nuijten M, Heigener DF, Bischoff HG, et al. Effectiveness of bevacizumab-and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 2010;69(S1):S4-S10
34. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-smallcell lung cancer. J Clin Oncol 2009;27:3217-24
35. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-40
36. Correale P, Botta C, Basile A, et al. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2011; 12:112-18
37. Correale P, Remondo C, Carbone SF, et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the antiangiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2010; 9:685-93